TY - JOUR
T1 - Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
AU - Prulière-Escabasse, V.
AU - Escudier, E.
AU - Balheda, R.
AU - Soria, J. C.
AU - Coste, A.
AU - Massard, C.
PY - 2009/6/1
Y1 - 2009/6/1
N2 - Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal symptoms including symptomatic rhinitis and epistaxis. For the first time, a new entity of "atrophic rhinitis" induced by angiogenesis inhibitors is described and revealed that angiogenesis inhibitors alter the differentiation of nasal epithelium. VEGF may act on epithelial cell proliferation and differentiation in nasal epithelium.
AB - Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal symptoms including symptomatic rhinitis and epistaxis. For the first time, a new entity of "atrophic rhinitis" induced by angiogenesis inhibitors is described and revealed that angiogenesis inhibitors alter the differentiation of nasal epithelium. VEGF may act on epithelial cell proliferation and differentiation in nasal epithelium.
KW - Angiogenic therapy
KW - Epistaxis
KW - Rhinitis
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=64649086956&partnerID=8YFLogxK
U2 - 10.1007/s10637-008-9168-6
DO - 10.1007/s10637-008-9168-6
M3 - Article
C2 - 18754078
AN - SCOPUS:64649086956
SN - 0167-6997
VL - 27
SP - 285
EP - 286
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -